pegfilgrastim Active substance pegfilgrastimDomain Oncology and HematologyReason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)Main indication Hematology otherExtended indication In combination with plinabulin in patients with chemotherapy-induced neutropenia. 1. Product Manufacturer BeyondspringMechanism of action OtherRoute of administration IntravenousTherapeutical formulation Intravenous dripBudgetting framework Intermural (MSZ)Additional comments Guanine nucleotide exchange factor stimulant 2. Registration Registration route Centralised (EMA)Submission date June 2020Expected Registration July 2021Registration phase Registration application pending 3. Therapeutic value Current treatment options PegfilgrastimTherapeutic value No judgementDuration of treatment Average 12 week / weeksFrequency of administration 1 times every 3 weeksDosage per administration 40 mgReferences NCT03294577 4. Expected patient volume per year There is currently nothing known about the expected patient volume. 5. Expected cost per patient per year There is currently nothing known about the expected cost. 6. Potential total cost per year There is currently nothing known about the possible total cost. 7. Off label use There is currently nothing known about off label use. 8. Indication extension Indication extension YesIndication extensions Non-small cell lung cancerReferences clincaltrials.govAdditional comments Lopende fase 3 studie 9. Other information There is currently no futher information available.